Medable

12/08/2025

Where holiday spirit meets getting it done. 🤝

12/05/2025

Generative AI is moving from “interesting” to “operational” in clinical trials.
Next week, Medable CMO Dr. Pamela Tenaerts joins the CVCT Forum to share how GenAI can streamline CV study ex*****on, including faster, smarter eCOA creation and enhanced localization.

👉 Don’t miss this live session; register now: https://www.globalcvctforum.com
________

12/03/2025

Your eCOA is "fine," but you're looking for great?
In Everest Group’s 2025 Life Sciences eCOA Products PEAK Matrix® Assessment, Medable was named a Leader against 19 industry providers based on several key factors:

🟣 Buyer priorities—ease of use, integration, domain expertise, and flexible pricing.
🟣 Innovation drivers—AI-driven study setup, analytics integration, and patient engagement tools.
🟣 Future focus—AI as an enabler, not the end goal—patient experience and real-time access remain central.

Looking forward, with the recent launch of our Agent Studio, Team Medable is poised to reimagine the clinical trial lifecycle even further. We're giving sponsors and CROs the power to build and deploy agents that automate manual work across assessment builds, remove bottlenecks, and accelerate trial outcomes.

👉 Learn more here: https://www.medable.com/newsroom/medable-named-a-leader-amid-growing-ecoa-adoption
________

11/28/2025

“As soon as I know a competitor has decided to build something itself, I know it has lost.”
When top pharma CEOs say this about innovation, you have to ask: what do they know that others don’t?

The truth is, the gap between an impressive AI prototype and a validated, clinical-grade solution is enormous. This guide breaks down the hidden costs, the failure patterns, and the smartest path forward.

Read here: https://www.medable.com/knowledge-center/blog-build-vs-buy-a-guide-on-adopting-ai-agents-for-life-sciences
________

11/27/2025

If a participant can’t understand the study or use the trial technologies, they’re already excluded—long before the screening visit.

That silent choke point slows drug development, and as health literacy gaps widen while digital methodologies expand, the industry has hit an inflection point.

Dr Pamela Tenaerts explains what’s not working, how we can correct course, and why progress now depends on comprehension, usability, and a patient experience built for real people.

Read here: https://www.acrohealth.org/informed-content-hub/reimagining-health-literacy-in-the-digital-era/
________

Written by: Pamela Tenaerts, MD, MBA, Chief Medical Officer at Medable Fully 36% of Americans have limited health literacy skills, and among indigent and minority patients in urban areas, this number rises to over 80%.1 That is not just surprising, but unsettling. Health literacy is a foundational c...

11/25/2025

As we recognize National Diabetes Awareness Month, one truth stands out: every delay in clinical development is a costly delay for patients.
That’s why—in a pivotal Phase III diabetes study—a top-10 pharma sponsor rethought traditional delivery and closeout processes, pushing past bottlenecks and accelerating the path to a much-needed therapy.

When innovation meets urgency, patients win. Learn more here: https://www.medable.com/knowledge-center/long-form-setting-a-new-client-standard-in-study-closeout-timelines
________

11/18/2025

Drowning in oversight meetings? Stuck waiting on translations? Still building studies the slow way? Time for a technology upgrade. 🎥

Experience live how leading clinical teams using Study Studio are now:
🟣 Replacing 3 meetings with just 1
🟣 Generating eCOAs up to 35X faster
🟣 Slashing localization timelines by 75%
🟣 Winning back up to 6 weeks to focus on science and patients

👉 Save your seat now: https://globalmeet.webcasts.com/starthere.jsp?ei=1738656&tp_key=d42bde5532
________

11/14/2025

The most striking theme at ESMO AI & Digital 2025 wasn’t about algorithms. It was about trust. The spotlight shifted from theoretical models to real-world adoption—AI tools that reduce friction in trials, modernize monitoring, and strengthen continuity of care.

Read the takeaways from Berlin and see how AI is finally moving from concept to clinical impact in cancer research: https://www.medable.com/knowledge-center/blog-what-happened-at-esmo-ai-digital-2025
________

11/13/2025

If almost half of a drug's development time is spent in 'white space,' is progress taking a backseat to process?

Every protocol amendment, data query, and regulatory handoff adds friction to a framework already stretched to its edge.

Agentic AI changes the equation. It connects systems and automates time-draining admin, turning the in-between into forward motion.

If you're tired of pausing between clinical milestones, learn more from Medable's Andrew Mackinnon here: https://pharmaphorum.com/rd/leveraging-ai-agents-eliminate-white-space-clinical-trials
________

Human-AI collaboration has the potential to mitigate gross productivity gaps and establish a new standard of clinical trial efficiency.

11/12/2025

If you're tired of too many oversight meetings, localization delays, and study builds that take weeks instead of days, this virtual session is for you! 🎥

During a live demo, you'll see exactly how clinical teams are:
🟣 Consolidating 3 review meetings into just 1.
🟣 Building eCOAs 35X faster.
🟣 Cutting translation timelines by 75%,
🟣 Gaining up to 6 weeks back to focus on what matters: science and patients.

👉 Secure your spot here: https://globalmeet.webcasts.com/starthere.jsp?ei=1738656&tp_key=d42bde5532
________

11/10/2025

High patient retention ✅. Low operational burden ✅. No EDC required ✅.

The Medable platform is powering a decade-long, global long-term follow-up (LTFU) obesity study. At present, our customer has achieved a 97% patient retention rate without using a traditional EDC system, all while delivering a compliant, scalable, and cost-efficient approach.

👉 Learn more here: https://www.medable.com/knowledge-center/long-form-long-form-driving-a-high-adherence-ltfu-trial-without-an-edc
________

11/10/2025

Clinical trials are cracking under their own weight. They're too complex, too slow, and too manual.

That’s where Agentic AI comes in. Built to think, decide, and act alongside people to redefine trial ex*****on and outcomes.

Medable’s approach goes beyond automation, giving every team an intelligent partner that helps turn idle time into active progress across every phase of development.

Learn more here: https://www.medable.com/knowledge-center/guides-building-blocks-agentic-ai-is-transforming-trial-design-management-and-outcomes
________